Farhad Ravandi-Kashani

137PUBLICATIONS
326CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (137)

|Jul 18, 2026
Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.

|Jul 16, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage.

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Jun 22, 2026
Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

|Jun 15, 2026
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

|Jun 11, 2026
All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Pageof 23

Frequent Collaborators

96 joint publications

Tapan M Kadia

85 joint publications

Nicholas Short

84 joint publications

Hagop M Kantarjian

83 joint publications

Navel G Daver